Formal Endorsement of ISRS 2023 Guidelines

We are pleased to announce the official endorsement by Ontario Health-Cancer Care Ontario (OH-CCO) of the 2023 International Stereotactic Radiosurgery Society’s Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and International Stereotactic Radiosurgery Society Recommendations, published in the IJROBP – The Red Journal as open access

“Ontario Health (Cancer Care Ontario)’s endorsement of the ISRS Guideline on the Management of Brain Radiation Necrosis after SRS has been critical to our practitioner community in providing evidence-based recommendations to guide the treatment of cerebral radiation necrosis (cRN), and for gaining access to bevacizumab for treatment of resistant, symptomatic disease. It is also supporting work regarding access to perfusion imaging with MRI to guide bevacizumab treatment” said Dr. Sunit Das CNS Cancers Lead, Cancer Care Integration & Disease Advisory Program, Ontario Health (Cancer Care Ontario).

For OH-CCO, this guideline endorsement is to provide clinicians with evidence-based recommendations on the management of a complex patient population presenting with symptomatic brain radiation necrosis after stereotactic radiosurgery in Ontario. This endorsed guideline will help improve the quality of patient care by providing an evidence-based approach for healthcare providers to follow.

Dr.Arjun Sahgal, President of ISRS, shared this exciting news on LinkedIn.

“Ontario Health-Cancer Care Ontario takes a step towards further improving and standardizing the management of brain necrosis following stereotactic radiosurgery, by endorsing the International Stereotactic Radiosurgery Society (ISRS) guideline published in the IJROBP – The Red Journal as open access. I couldn’t be more proud and grateful to my province of Ontario for this step forward.”

See the abstract from OH-CCO, as well as the full endorsement and quality initiative report: